Finanzen von DENTSPLY SIRONA Inc (XRAY)XRAYDENTSPLY SIRONA Inc

DENTSPLY SIRONA Inc. (XRAY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Implants & Prosthetics, accounting for 17.5% of total sales, equivalent to $157.00M. Other significant revenue streams include Equipment & Instruments and CAD/CAM. Understanding this composition is critical for investors evaluating how XRAY navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, DENTSPLY SIRONA Inc. maintains a gross margin of 54.90%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.35%, while the net margin is 4.01%. These profitability ratios, combined with a Return on Equity (ROE) of -32.98%, provide a clear picture of how effectively XRAY converts its operational activities into shareholder value.

In the context of the broader market, XRAY competes directly with industry leaders such as ESTA and NVCR. With a market capitalization of $1.70B, it holds a significant position in the sector. When comparing efficiency, XRAY's gross margin of 54.90% stands against ESTA's 70.64% and NVCR's 77.61%. Such benchmarking helps identify whether DENTSPLY SIRONA Inc. is trading at a premium or discount relative to its financial performance.

DENTSPLY SIRONA reported a Q2 2026 revenue of $898 million, down 4.1% year-over-year, but beat estimates. The adjusted EPS was $0.52, surpassing the consensus estimate of $0.36 by 44.4%. Gross margin improved to 54.90%, indicating effective cost management despite challenges.